Clinical Trial Update: The Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HC022 Injection in Subjects With SLE/CLE [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of HC022 injection in systemic lupus erythematos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Lupus Erythematosus
• Systemic Lupus Erythematosus

Drugs mentioned

• HC022 injection

Snippet

Sponsor: HC Biopharma Inc. | Conditions: Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE) | Phase 1 | Status: NOT_YET_RECRUITING